BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 24113009)

  • 1. [Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
    Wang B; Wang B; Zhang L; Chu X; Yu G
    Zhongguo Fei Ai Za Zhi; 2013 Oct; 16(10):547-52. PubMed ID: 24113009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of EGFR or KRAS and expression of chemotherapy-related genes based on small biopsy samples in stage IIIB and IV inoperable non-small cell lung cancer.
    Deng LL; Deng HB; Lu CL; Guo Y; Wang D; Yan CH; Lv X; Shao YX
    J Cancer Res Clin Oncol; 2014 Dec; 140(12):2097-105. PubMed ID: 24994038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between clinical characteristics and oncogene expression in patients with non-small cell lung cancer.
    Han Y; Yu DP; Zhou SJ; Song XY; Li YS; Xiao N; Liu ZD; Sun XJ; Zhao QY; Liu SK
    Genet Mol Res; 2014 Oct; 13(4):8913-24. PubMed ID: 25366782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of rearrangement of ALK, ROS1, somatic mutation of EGFR, KRAS, BRAF, PIK3CA, and mRNA expression of ERCC1, TYMS, RRM1, TUBB3, EGFR in patients with non-small cell lung cancer and their clinical significance.
    Zhang Q; Sun T; Kang P; Qian K; Deng B; Zhou J; Wang R; Jiang B; Li K; Liu F; Wu S; Tan Q
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):583-93. PubMed ID: 26842788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
    Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
    J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts.
    Li S; Li L; Zhu Y; Huang C; Qin Y; Liu H; Ren-Heidenreich L; Shi B; Ren H; Chu X; Kang J; Wang W; Xu J; Tang K; Yang H; Zheng Y; He J; Yu G; Liang N
    Br J Cancer; 2014 May; 110(11):2812-20. PubMed ID: 24743704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer.
    Cao Y; Zhang G; Wang P; Zhou J; Gan W; Song Y; Huang L; Zhang Y; Luo G; Gong J; Zhang L
    BMC Gastroenterol; 2017 Jan; 17(1):2. PubMed ID: 28056823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines.
    Messner I; Cadeddu G; Huckenbeck W; Knowles HJ; Gabbert HE; Baldus SE; Schaefer KL
    J Cancer Res Clin Oncol; 2013 Feb; 139(2):201-9. PubMed ID: 23015072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the IL-1β/EHD1/TUBB3 axis overcomes resistance to EGFR-TKI in NSCLC.
    Huang J; Lan X; Wang T; Lu H; Cao M; Yan S; Cui Y; Jia D; Cai L; Xing Y
    Oncogene; 2020 Feb; 39(8):1739-1755. PubMed ID: 31740781
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High TUBB3 expression, an independent prognostic marker in patients with early non-small cell lung cancer treated by preoperative chemotherapy, is regulated by K-Ras signaling pathway.
    Levallet G; Bergot E; Antoine M; Creveuil C; Santos AO; Beau-Faller M; de Fraipont F; Brambilla E; Levallet J; Morin F; Westeel V; Wislez M; Quoix E; Debieuvre D; Dubois F; Rouquette I; Pujol JL; Moro-Sibilot D; Camonis J; Zalcman G;
    Mol Cancer Ther; 2012 May; 11(5):1203-13. PubMed ID: 22411898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spectrum of somatic EGFR, KRAS, BRAF, PTEN mutations and TTF-1 expression in Brazilian lung cancer patients.
    Carneiro JG; Couto PG; Bastos-Rodrigues L; Bicalho MA; Vidigal PV; Vilhena A; Amaral NF; Bale AE; Friedman E; De Marco L
    Genet Res (Camb); 2014; 96():e002. PubMed ID: 24594201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of EGFR signaling pathway somatic DNA mutations derived from peripheral blood and corresponding tumor tissue of patients with advanced non-small-cell lung cancer using liquidchip technology.
    Zhang H; Liu D; Li S; Zheng Y; Yang X; Li X; Zhang Q; Qin N; Lu J; Ren-Heidenreich L; Yang H; Wu Y; Zhang X; Nong J; Sun Y; Zhang S
    J Mol Diagn; 2013 Nov; 15(6):819-26. PubMed ID: 23988622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer.
    Sunaga N; Kaira K; Imai H; Shimizu K; Nakano T; Shames DS; Girard L; Soh J; Sato M; Iwasaki Y; Ishizuka T; Gazdar AF; Minna JD; Mori M
    Oncogene; 2013 Aug; 32(34):4034-42. PubMed ID: 22964644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of TS, RRM1, ERCC1, TUBB3 and STMN1 Genes in Tissues of Non-small Cell Lung Cancer and its Significance in Guiding Postoperative Adjuvant Chemotherapy.
    Zou ZQ; Du YY; Sui G; Xu SN
    Asian Pac J Cancer Prev; 2015; 16(8):3189-94. PubMed ID: 25921119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a reference material panel for detecting
    Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
    J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.
    Hassanein SS; Ibrahim SA; Abdel-Mawgood AL
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers.
    Lee SY; Kim MJ; Jin G; Yoo SS; Park JY; Choi JE; Jeon HS; Cho S; Lee EB; Cha SI; Park TI; Kim CH; Jung TH; Park JY
    J Thorac Oncol; 2010 Nov; 5(11):1734-40. PubMed ID: 20881644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer.
    Hoque MO; Brait M; Rosenbaum E; Poeta ML; Pal P; Begum S; Dasgupta S; Carvalho AL; Ahrendt SA; Westra WH; Sidransky D
    J Thorac Oncol; 2010 Dec; 5(12):1887-93. PubMed ID: 21102258
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.